Click to verify BBB accreditation and to see a BBB

George Evans, the CEO of Cellceutix Corporation (OTCBB:CTIX) an emerging bio-pharmaceutical company in the business of developing small-molecule therapies in areas of unmet medical needs, stopped by SmallCapVoice.com to discuss his exciting young company. Currently the Company owns the rights to seven drug compounds, including Kevetrin, which it is developing as a treatment for certain cancers, and KM-133, which it is developing for psoriasis. For more information, visit: www.cellceutix.com.

  • Twitter
  • StumbleUpon
  • Facebook
  • LinkedIn
  • Technorati Favorites
  • Yahoo Buzz
  • Delicious
  • Digg
  • Fark
  • Google Buzz
  • NewsVine
  • Netvibes Share
  • PrintFriendly
  • Google Gmail
  • MySpace
  • Blogger Post
  • AOL Mail
  • Yahoo Bookmarks
  • Windows Live Spaces
  • WordPress
  • Yahoo Mail
  • Share/Bookmark

9 Responses to “10-5-09 Audio Interview with Cellceutix Corp. (OTCBB: CTIX)”

Subscribe to our feed
Subscribe